Pirtobrutinib is a type of targeted therapy known as a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that plays a key role in the signaling pathways of B-cells, which are a type of white blood cell involved in many blood cancers, including chronic lymphocytic leukemia (CLL). By blocking BTK, pirtobrutinib disrupts signals that help cancerous B-cells survive, grow, and spread.

Unlike some other BTK inhibitors, pirtobrutinib is a noncovalent (reversible) inhibitor and can bind to both normal BTK and BTK with certain mutations (such as C481 mutations) that may make other drugs less effective. This helps stop the growth of cancerous B-cells, leading to a reduction in disease activity. In clinical studies, pirtobrutinib has shown the ability to shrink tumors and control disease in patients who have already received other treatments, including other BTK inhibitors.

pirtobrutinib

Common brand names

Approved use in